Protocol

Continuous glucose monitoring (CGM) in non-diabetics

CGM · FreeStyle Libre · glucose sensor · metabolic monitoring · continuous glucose monitor

CGM has strong clinical evidence in diabetes, where it improves glycaemic control and is a regulated therapeutic device. That evidence does not transfer to the non-diabetic longevity use case. In healthy people, the case rests on mechanism (glycaemic variability and post-meal spikes are associated with metabolic risk markers) plus short-term behaviour-change data, not on outcome trials. There are no trials showing that wearing a CGM as a non-diabetic extends healthspan, reduces mortality, or prevents incident diabetes. Normal-range reference data for non-diabetics is also thin, so "spikes" flagged by consumer apps often fall within ordinary physiology, and the interpretive layer (scores, rankings, food grades) is proprietary and unvalidated. The honest read: a real, well-engineered measurement device wrapped in a healthspan narrative its own evidence base does not yet support. Note also that Vively's own material states Medicare does not cover CGM for non-diabetic individuals in Australia, which is a reimbursement fact and says nothing about approval status.

At a glance

Evidence
Commercial
Singapore (HSA)
No HSA position on file
Australia (TGA)
Not verified from a TGA source. Abbott's Australian FreeStyle Libre site states the labelled indication is "measuring interstitial fluid glucose levels in people (aged 2+) with diabetes" (FreeStyle Libre 2 Plus / 3 Plus), and for insulin-requiring diabetes aged 4+ for FreeStyle Libre 2 — i.e. non-diabetic wellness use sits outside the labelled indication. The ARTG entry number and the device's formal TGA inclusion status could NOT be confirmed from tga.gov.au (ARTG search unreachable during research), so no claim of TGA registration is made here. Separately, Vively states Medicare does not cover CGM for non-diabetic individuals in Australia, which is a reimbursement fact, not an approval fact. Treat regulatory status as unconfirmed pending a direct ARTG lookup.
Offered at
4 clinics

Singapore

Health Sciences Authority

HSA status
No position on file
In our SG set
Tracked in Singapore
SG clinics
2

Australia

Therapeutic Goods Administration

TGA status
Not verified from a TGA source. Abbott's Australian FreeStyle Libre site states the labelled indication is "measuring interstitial fluid glucose levels in people (aged 2+) with diabetes" (FreeStyle Libre 2 Plus / 3 Plus), and for insulin-requiring diabetes aged 4+ for FreeStyle Libre 2 — i.e. non-diabetic wellness use sits outside the labelled indication. The ARTG entry number and the device's formal TGA inclusion status could NOT be confirmed from tga.gov.au (ARTG search unreachable during research), so no claim of TGA registration is made here. Separately, Vively states Medicare does not cover CGM for non-diabetic individuals in Australia, which is a reimbursement fact, not an approval fact. Treat regulatory status as unconfirmed pending a direct ARTG lookup.
In our AU set
Tracked in Australia
AU clinics
2
Evidence is not approvalAn evidence grade describes how strong the science is. A regulatory status describes whether a body has approved the intervention for an indication. They are different questions, answered separately above.

What it is

Plain-language explainer

A continuous glucose monitor is a small sensor worn on the upper arm that samples glucose in interstitial fluid every few minutes and streams the readings to a phone app. In diabetes care it is a well-established clinical tool. In the longevity market it is sold to people without diabetes as a "metabolic health" instrument, on the claim that seeing your own glucose response to meals, exercise and sleep will drive dietary changes that improve long-term metabolic health.

Categories

Protocol

Offered by

Where variis has verified this protocol (4)

Keep reading

Related coverage from the newsroom.

Suggest an updateJoin the community

Every entity profile on variis is sourced. Not medical advice.